Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Vildagliptin tablets, which are indicated for the treatment of type 2 diabetes [1] Group 1: Product Information - Vildagliptin is a selective Dipeptidyl Peptidase-4 (DPP-4) inhibitor that quickly suppresses DPP-4 activity after administration [1] - The drug increases the levels of endogenous glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), enhancing the sensitivity of β-cells to glucose and promoting glucose-dependent insulin secretion [1] - Vildagliptin also increases the sensitivity of α-cells to glucose, improving the alignment between glucose levels and glucagon secretion [1] Group 2: Mechanism of Action - During hyperglycemia, Vildagliptin elevates the levels of intestinal glucagon-like peptides, increasing the insulin/glucagon ratio [1] - This leads to a reduction in hepatic glucose production during fasting and postprandial states, thereby lowering blood glucose levels [1]
新天地取得一项药品注册证书